Regeneron's Eylea wins US OK; bests Lucentis in pricing, dosing
This article was originally published in Scrip
Executive Summary
Regeneron finally got its wet age-related macular degeneration (AMD) drug Eylea (aflibercept) over the finish line on 18 November, with the US FDA granting its blessing to the drug.